Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Pirlindole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.97 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.97 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.97 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.97 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.97 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.97 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.97 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.97 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.97 |
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.72 |
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.97 |
| ▸ | MEN1 | O00255 | 6/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.97 |
| ▸ | TP53 | P04637 | 3/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | TEAD4 | Q15561 | 2/20 | 0.97 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pirlindole SCHEMBL18878061 | 0.99 | HSD17B10 (1.00) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| Pirlindole SCHEMBL373564 | 0.99 | HSD17B10 (1.00) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| Pirlindole SCHEMBL18877133 | 0.99 | HSD17B10 (1.00) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| Pirlindole SCHEMBL29500947 | 0.99 | HSD17B10 (1.00) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| Pirlindole SCHEMBL1649683 | 0.96 | HSD17B10 (0.95) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| SCHEMBL4152460 | 0.93 | HSD17B10 (1.00) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| Pirlindole SCHEMBL30984462 | 0.91 | HSD17B10 (1.00) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| Pirlindole SCHEMBL3761340 | 0.91 | HSD17B10 (1.00) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| Hydrochloric Acid SCHEMBL9849090 | 0.82 | KMT2A (0.98) | HSD17B10MEN1KMT2AKDM4ECYP1A2 | |
| Pirlindole SCHEMBL17241165 | 0.82 | HSD17B10 (0.68) | HSD17B10MEN1KMT2AKDM4ECYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10172854-B2 | Compositions and methods for treating mitochondrial diseases | BIOVISTA, INC. (US) | 2019-01-08 | — | — | US | claimed |
| US-20180110775-A1 | COMPOSITIONS AND METHODS FOR TREATING MITOCHONDRIAL DISEASES | BIOVISTA INC (US) | 2018-04-26 | — | — | US | claimed |
| CN-104774208-A | Preparation method of deuterium-labeled pirlindole hydrochloride | TLC PHARMACHEM INC | 2015-07-15 | — | — | CN | claimed |
| EP-1044976-B1 | Process for the preparation of pirlindole hydrochloride | ERREGIERRE SPA (IT) | 2002-07-24 | — | — | EP | claimed |
| EP-1044976-A1 | Process for the preparation of pirlindole hydrochloride | ERREGIERRE S.p.A. (IT) | 2000-10-18 | — | — | EP | claimed |
| EP-3831385-B1 | MANDELATE SALTS OF PIRLINDOLE ENANTIOMERS FOR USE IN MEDICINE | TECNIMEDE SOCIEDADE TECNICO MEDICINAL S (PT) | 2024-07-10 | — | — | EP | disclosed |
| CN-110831943-B | Method for producing piperazine rings for the synthesis of pyrazinocarbazole derivatives | 社会医疗技术员技术股份公司 | 2022-05-03 | — | — | CN | disclosed |
| CN-110914270-B | Preparation method of pirlindole enantiomer and salt thereof | 社会医疗技术员技术股份公司 | 2022-05-03 | — | — | CN | disclosed |
| EP-3612534-B1 | PROCESS FOR THE PREPARATION OF PIPERAZINE RING FOR THE SYNTHESIS OF PYRAZINOCARBAZOLE DERIVATIVES | TECNIMEDE SOCIEDADE TECNICO MEDICINAL SA (PT) | 2021-12-22 | — | — | EP | disclosed |
| US-11008327-B2 | Processes for the preparation of pharmaceutically acceptable salts of (R)-Pirlindole and (S)-Pirlindole | TECNIMEDE, SOCIEDADE TÉCNICO-MEDICINAL, SA (PT) | 2021-05-18 | — | — | US | disclosed |
| CN-106456637-B | Pharmaceutical use of (S) -pirlindole and pharmaceutically acceptable salts thereof | 特克尼梅德医疗技术股份公司 | 2020-06-09 | — | — | CN | disclosed |
| US-20200131186-A1 | PROCESS FOR THE PREPARATION OF PIPERAZINE RING FOR THE SYNTHESIS OF PYRAZINOCARBAZOLE DERIVATIVES | TECNIMEDE, SOCIEDADE TÉCNICO-MEDICINAL, SA (PT) | 2020-04-30 | — | — | US | disclosed |
| CN-1810789-A | Prepn of-2-(N-carbazolyl)-ethoxy carbohydrazide | DALIAN CHEMICAL PHYSICS INST (CN) | 2006-08-02 | — | — | CN | disclosed |
| EP-1300140-B1 | Long release matricial formulations of pirlindol hydrochloride | TECNIMEDE SOCIEDADE TECNICO MEDICINAL SA (PT) | 2005-11-30 | — | — | EP | disclosed |
| EP-1044976-B1 | Process for the preparation of pirlindole hydrochloride | ERREGIERRE SPA (IT) | 2002-07-24 | — | — | EP | disclosed |
| EP-1044976-B1 | Process for the preparation of pirlindole hydrochloride | ERREGIERRE SPA (IT) | 2002-07-24 | — | — | EP | disclosed |
| EP-1044976-A1 | Process for the preparation of pirlindole hydrochloride | ERREGIERRE S.p.A. (IT) | 2000-10-18 | — | — | EP | disclosed |
| EP-1044976-A1 | Process for the preparation of pirlindole hydrochloride | ERREGIERRE S.p.A. (IT) | 2000-10-18 | — | — | EP | disclosed |
| EP-1044976-A1 | Process for the preparation of pirlindole hydrochloride | ERREGIERRE S.p.A. (IT) | 2000-10-18 | — | — | EP | disclosed |
| EP-0457908-A1 | HYDROCHLORIDE 2,3,3a,4,5,6-HEXAHYDRO-8-CYCLOHEXYL-1H-PYRAZINO (3,2,1-j,k)CARBAZOL, METHOD OF OBTAINING IT AND A PHARMACEUTICAL PREPARATION OF ANTIDEPRESSIVE ACTION BASED ON IT | VSESOJUZNY NAUCHNO-ISSLEDOVATELSKY KHIMIKO-FARMATSEVTICHESKY INST. IMENI SERGO ORDZHONIKIDZE (VNIKHFI) (SU) | 1991-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10172854-B2 | Compositions and methods for treating mitochondrial diseases | MT-ND2, CS, UQCRC2 | HTR1A 4403/4885ADRA2A 3910/4885CHRM1 4724/4885 |
| US-20180110775-A1 | COMPOSITIONS AND METHODS FOR TREATING MITOCHONDRIAL DISEASES | MT-ND2, CS, UQCRC2 | HTR1A 4403/4885ADRA2A 3910/4885CHRM1 4724/4885 |
| US-11008327-B2 | Processes for the preparation of pharmaceutically acceptable salts of (R)-Pirlindole and (S)-Pirlindole | PIR, DRD5, DRD1 | HTR1A 63/4885ADRA2A 871/4885CHRM1 698/4885 |
| US-20200131186-A1 | PROCESS FOR THE PREPARATION OF PIPERAZINE RING FOR THE SYNTHESIS OF PYRAZINOCARBAZOLE DERIVATIVES | PIR, CYP3A5, DRD5 | HTR1A 134/4885ADRA2A 1622/4885CHRM1 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.